Key result
Ginsenoside Rf ameliorated the transcription of ANXA2, BAZ1A, DNMT3L, and MMP9 in an FFA-induced HepG2 cell model, suggesting potential therapeutic effects for early-stage NAFLD.
Why the study?
Ginsenoside Rf relieves lipid metabolism and inflammatory reactions, but the underlying mechanisms for treating early-stage NAFLD remained to be revealed.
Ginsenoside Rf demonstrates potential pharmacological effects in reversing early-stage nonalcoholic fatty liver disease through modulation of specific gene targets in preclinical models.
Ginsenoside Rf mechanisms in early NAFLD remain exploratory; leaves open clinical translation pending prospective trials.
OBJECTIVE: Ginsenoside Rf, a tetracyclic triterpenoid only present in Panax ginseng, has been proven to relieve lipid metabolism and inflammatory reactions, which can be a potential treatment for nonalcoholic fatty liver disease (NAFLD). Therefore, this study aimed to reveal the underlying mechanisms of ginsenoside Rf in the treatment of early-stage NAFLD (NAFL) by using a bioinformatics method and biological experiments. METHODS: Target genes associated with NAFL were screened from the Gene Expression Omnibus (GEO) database, a database repository of high-throughput gene expression data and hybridization arrays, chips, and microarrays. Subsequently, gene set enrichment analysis was performed by using Gene Ontology enrichment analysis tool. Then, the binding capacity between ginsenoside Rf and NAFL-related targets was evaluated by molecular docking. Finally, the FFA-induced HepG2 cell model treated with ginsenoside Rf was adopted to verify the effect of ginsenoside Rf and the related mechanisms. RESULTS: There were 41 common differentially expressed genes in the GEO dataset. Gene Ontology and Reactome pathway enrichment analysis of the differentially expressed genes showed that many pathways could be related to the pathogenesis of NAFL, including those participating in the cytokine-mediated signaling pathway, G protein-coupled receptor signaling pathway, and response to lipopolysaccharide. Finally, the qRT-PCR analysis results indicated that ginsenoside Rf therapy could ameliorate the transcription of ANXA2, BAZ1A, DNMT3L and MMP9. CONCLUSION: Our research discovered the relevant mechanisms and basic pharmacological effects of ginsenoside Rf in the treatment of NAFL. These results might facilitate the development of ginsenoside Rf as an alternative medication for NAFL.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied early-stage nonalcoholic fatty liver disease (NAFL). Ginsenoside Rf was evaluated on transcription of ANXA2, BAZ1A, DNMT3L and MMP9. Ginsenoside Rf ameliorated the transcription of ANXA2, BAZ1A, DNMT3L, and MMP9 in an FFA-induced HepG2 cell model, suggesting potential therapeutic effects for early-stage NAFLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: